{"id":{"repo_id":"birmingham","oai_identifier":"oai:etheses.bham.ac.uk:15954"},"canonical_url":"https://search.ndltd.org/etd/birmingham/oai:etheses.bham.ac.uk:15954","repository":{"repo_id":"birmingham","name":"University of Birmingham","base_url":"https://etheses.bham.ac.uk/cgi/oai2"},"display":{"title":"Optimising CAR-T cells for enhanced activity in the tumour microenvironment","abstract":"Acute myeloid leukaemia is a cancer of the myeloid cells in the bone marrow. AML alters the bone marrow niche, creating an immunosuppressive microenvironment. AML increases tryptophan metabolism and cystine uptake. T-cells require sufficient nutrients to function. Due to a lack of clinical activity, CAR T-cell therapies are currently only used in a limited number of cancers. We hypothesised that the lack of nutrients in the AML microenvironment supresses CAR T-cell function. This work discusses how the availability of tryptophan and cystine affected T-cell and CAR T-cell proliferation. We designed CAR T-cells with the overexpression of tryptophan or cystine transporters, SLC7A5 and SLC7A11, respectively. We first demonstrated that the addition of SLC7A5 and SLC7A11 to Jurkat CAR T-cells provided increased metabolic rates in low tryptophan and cystine environments, respectively. The addition of SLC7A5 and SLC7A11 to CAR T-cells increased tryptophan and cystine uptake, respectively. CAR T-cells with SLC7A5 or SLC7A11 overexpression had increased proliferation in low tryptophan and cystine environments, respectively. The CAR T-cells with overexpression of SLC7A5 and SLC7A11 improved cancer clearance in murine models. Performing RNA sequencing of CAR-T cells following interaction with tumour cells, we showed a significant alteration of pathways associated with T-cell activation, metabolism, and migration, caused by the addition of the transporters to the CAR T-cells. These results demonstrate that the addition of SLC7A5 and SLC7A11 could improve CAR T-cell function in low amino acid environments.","abstract_html":"Acute myeloid leukaemia is a cancer of the myeloid cells in the bone marrow. AML alters the bone marrow niche, creating an immunosuppressive microenvironment. AML increases tryptophan metabolism and cystine uptake. T-cells require sufficient nutrients to function. Due to a lack of clinical activity, CAR T-cell therapies are currently only used in a limited number of cancers. We hypothesised that the lack of nutrients in the AML microenvironment supresses CAR T-cell function. This work discusses how the availability of tryptophan and cystine affected T-cell and CAR T-cell proliferation. We designed CAR T-cells with the overexpression of tryptophan or cystine transporters, SLC7A5 and SLC7A11, respectively. We first demonstrated that the addition of SLC7A5 and SLC7A11 to Jurkat CAR T-cells provided increased metabolic rates in low tryptophan and cystine environments, respectively. The addition of SLC7A5 and SLC7A11 to CAR T-cells increased tryptophan and cystine uptake, respectively. CAR T-cells with SLC7A5 or SLC7A11 overexpression had increased proliferation in low tryptophan and cystine environments, respectively. The CAR T-cells with overexpression of SLC7A5 and SLC7A11 improved cancer clearance in murine models. Performing RNA sequencing of CAR-T cells following interaction with tumour cells, we showed a significant alteration of pathways associated with T-cell activation, metabolism, and migration, caused by the addition of the transporters to the CAR T-cells. These results demonstrate that the addition of SLC7A5 and SLC7A11 could improve CAR T-cell function in low amino acid environments.","abstract_has_math":false,"creators":["McJannett, Nicola Jane"],"institution":"University of Birmingham","degree_name":"d_ph","degree_level":"d_ph","degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2025,"date_issued":"2025-07","date_published":"2025-07","updated_at":"2026-11-19T09:33:06Z","subjects":["Q Science (General)","R Medicine (General)"],"languages":["eng"],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":null,"outbound_label":null,"outbound_source":null,"record_url":null,"record_label":null,"record_kind":null,"record_source":null,"download_url":"http://etheses.bham.ac.uk//id/eprint/15954/1/McJannett2025PhD.pdf","download_label":"Download PDF","download_source":"dc:identifier.uri","access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://etheses.bham.ac.uk/cgi/oai2?verb=GetRecord&metadataPrefix=uketd_dc&identifier=oai%3Aetheses.bham.ac.uk%3A15954","prefix":"uketd_dc"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.sponsor","label":"Sponsor","values":["other"]},{"key":"dc:creator","label":"Author","values":["McJannett, Nicola Jane"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date","label":"Dc Date","values":["2025-07"]},{"key":"dc:date.issued","label":"Date","values":["2025-07"]},{"key":"dc:publisher.department","label":"Dc Publisher Department","values":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"]},{"key":"dc:publisher.institution","label":"Dc Publisher Institution","values":["University of Birmingham"]},{"key":"dc:relation.isreferencedby","label":"Dc Relation Isreferencedby","values":["http://etheses.bham.ac.uk//id/eprint/15954/"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]},{"key":"dc:type.qualificationlevel","label":"Dc Type Qualificationlevel","values":["d_ph"]},{"key":"dc:type.qualificationname","label":"Dc Type Qualificationname","values":["d_ph"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Q Science (General)","R Medicine (General)"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.dcterms_iso639_2","label":"Language (ISO 639-2)","values":["eng"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://etheses.bham.ac.uk//id/eprint/15954/1/McJannett2025PhD.pdf"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Acute myeloid leukaemia is a cancer of the myeloid cells in the bone marrow. AML alters the bone marrow niche, creating an immunosuppressive microenvironment. AML increases tryptophan metabolism and cystine uptake. T-cells require sufficient nutrients to function. Due to a lack of clinical activity, CAR T-cell therapies are currently only used in a limited number of cancers. We hypothesised that the lack of nutrients in the AML microenvironment supresses CAR T-cell function. This work discusses how the availability of tryptophan and cystine affected T-cell and CAR T-cell proliferation. We designed CAR T-cells with the overexpression of tryptophan or cystine transporters, SLC7A5 and SLC7A11, respectively. We first demonstrated that the addition of SLC7A5 and SLC7A11 to Jurkat CAR T-cells provided increased metabolic rates in low tryptophan and cystine environments, respectively. The addition of SLC7A5 and SLC7A11 to CAR T-cells increased tryptophan and cystine uptake, respectively. CAR T-cells with SLC7A5 or SLC7A11 overexpression had increased proliferation in low tryptophan and cystine environments, respectively. The CAR T-cells with overexpression of SLC7A5 and SLC7A11 improved cancer clearance in murine models. Performing RNA sequencing of CAR-T cells following interaction with tumour cells, we showed a significant alteration of pathways associated with T-cell activation, metabolism, and migration, caused by the addition of the transporters to the CAR T-cells. These results demonstrate that the addition of SLC7A5 and SLC7A11 could improve CAR T-cell function in low amino acid environments."]},{"key":"dc:format","label":"Dc Format","values":["text"]},{"key":"dcterms:accessrights","label":"Dcterms Accessrights","values":["public"]},{"key":"dc:title","label":"Title","values":["Optimising CAR-T cells for enhanced activity in the tumour microenvironment"]}]}],"canonical_facts":{"dc:contributor.sponsor":["other"],"dc:creator":["McJannett, Nicola Jane"],"dc:date":["2025-07"],"dc:date.issued":["2025-07"],"dc:description.abstract":["Acute myeloid leukaemia is a cancer of the myeloid cells in the bone marrow. AML alters the bone marrow niche, creating an immunosuppressive microenvironment. AML increases tryptophan metabolism and cystine uptake. T-cells require sufficient nutrients to function. Due to a lack of clinical activity, CAR T-cell therapies are currently only used in a limited number of cancers. We hypothesised that the lack of nutrients in the AML microenvironment supresses CAR T-cell function. This work discusses how the availability of tryptophan and cystine affected T-cell and CAR T-cell proliferation. We designed CAR T-cells with the overexpression of tryptophan or cystine transporters, SLC7A5 and SLC7A11, respectively. We first demonstrated that the addition of SLC7A5 and SLC7A11 to Jurkat CAR T-cells provided increased metabolic rates in low tryptophan and cystine environments, respectively. The addition of SLC7A5 and SLC7A11 to CAR T-cells increased tryptophan and cystine uptake, respectively. CAR T-cells with SLC7A5 or SLC7A11 overexpression had increased proliferation in low tryptophan and cystine environments, respectively. The CAR T-cells with overexpression of SLC7A5 and SLC7A11 improved cancer clearance in murine models. Performing RNA sequencing of CAR-T cells following interaction with tumour cells, we showed a significant alteration of pathways associated with T-cell activation, metabolism, and migration, caused by the addition of the transporters to the CAR T-cells. These results demonstrate that the addition of SLC7A5 and SLC7A11 could improve CAR T-cell function in low amino acid environments."],"dc:format":["text"],"dc:identifier.uri":["http://etheses.bham.ac.uk//id/eprint/15954/1/McJannett2025PhD.pdf"],"dc:language.dcterms_iso639_2":["eng"],"dc:publisher.department":["College of Medical & Dental Sciences","Institute of Immunology and Immunotherapy"],"dc:publisher.institution":["University of Birmingham"],"dc:relation.isreferencedby":["http://etheses.bham.ac.uk//id/eprint/15954/"],"dc:subject":["Q Science (General)","R Medicine (General)"],"dcterms:accessrights":["public"],"dc:title":["Optimising CAR-T cells for enhanced activity in the tumour microenvironment"],"dc:type":["Thesis"],"dc:type.qualificationlevel":["d_ph"],"dc:type.qualificationname":["d_ph"]},"updated_at":"2026-11-19T09:33:06Z"}